NCT06193980 ICU Combined Assessment of Cardio-Respiratory Exercise
| NCT ID | NCT06193980 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Manitoba |
| Condition | ICU Acquired Weakness |
| Study Type | OBSERVATIONAL |
| Enrollment | 50 participants |
| Start Date | 2023-12-15 |
| Primary Completion | 2029-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 50 participants in total. It began in 2023-12-15 with a primary completion date of 2029-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study aims to investigate how sepsis and critical illness can impair the cardiovascular system and microcirculation in intensive care unit (ICU) patients, which can lead to long-lasting muscle weakness/dysfunction or ICU-Acquired Weakness (ICU-AW) and exercise limitations.
Eligibility Criteria
Inclusion Criteria: * Patients who have received mechanical ventilation for at least 7 days in the intensive care unit (ICU) and have subsequently been discharged from hospital. Exclusion Criteria: * Unable to provide consent * Trajectory of health expected to be significantly limited in the upcoming 12 months * those who self-report that they cannot climb at least one flight of stairs due to limited exercise capacity * have significant orthopedic or musculoskeletal impairment affecting mobility * have a medical history of neuromuscular disease * ongoing respiratory limitations (i.e., supplemental oxygen) * significant heart disease (i.e. ejection fraction less than 30%, unstable ischemic heart disease, severe valvular heart disease) * a body mass index (BMI) of ≥ 40 kg/m2 (impacting NIRS signal due to adipose tissue thickness) * if participant's primary residence is a significant distance from the participating study site
Contact & Investigator
Asher Mendelson, MD PhD
PRINCIPAL INVESTIGATOR
University of Manitoba
Frequently Asked Questions
Who can join the NCT06193980 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying ICU Acquired Weakness. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06193980 currently recruiting?
Yes, NCT06193980 is actively recruiting participants. Contact the research team at Asher.Mendelson@umanitoba.ca for enrollment information.
Where is the NCT06193980 trial being conducted?
This trial is being conducted at Winnipeg, Canada, Winnipeg, Canada.
Who is sponsoring the NCT06193980 clinical trial?
NCT06193980 is sponsored by University of Manitoba. The principal investigator is Asher Mendelson, MD PhD at University of Manitoba. The trial plans to enroll 50 participants.